FDA and EMA regulatory submissions differ significantly in their dossier structure, review processes, and approval frameworks. The FDA operates under US federal law and follows its own submission formats and pathways, while the EMA applies EU pharmaceutical legislation and a centralised procedure covering all Member States. Understanding these differences is essential for any company planning a global market entry strategy.
What are the main structural differences between an FDA and EMA submission dossier?
Both agencies use the Common Technical Document (CTD) format as the foundation for regulatory submissions, but the way each agency applies and extends that format differs considerably. The FDA requires electronic submissions through its eCTD gateway, while the EMA accepts submissions through the European Medicines Agency’s eSubmission portal. Beyond the shared CTD backbone, the content requirements, labelling conventions, and supporting documentation diverge in meaningful ways.
The FDA places particular emphasis on its own labelling standards, including the Prescribing Information format governed by 21 CFR Part 201. The EMA, by contrast, requires a Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), and labelling that comply with EU Directive and Regulation requirements. Risk management documentation also differs: the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) only when specific safety concerns warrant it, whereas the EMA requires a Risk Management Plan (RMP) as a standard component of every marketing authorisation application.
- Module 1 is region-specific in both systems and contains administrative and prescribing information tailored to each jurisdiction
- Modules 2 to 5 follow the international CTD structure, but the level of detail expected, particularly in Module 3 (quality/CMC), can differ based on agency guidance
- The EMA requires an Environmental Risk Assessment (ERA) for most new active substances; the FDA does not have an equivalent mandatory requirement for human medicines
How do FDA and EMA review timelines compare?
FDA review timelines depend heavily on the designation a product receives. A standard New Drug Application (NDA) or Biologics License Application (BLA) has a 12-month review clock, while Priority Review shortens this to 6 months. Breakthrough Therapy and Accelerated Approval designations can further compress timelines for products addressing serious unmet needs.
The EMA’s centralised procedure runs on a 210-day active review clock, though the clock stops during periods when the applicant must respond to questions (Day 120 and Day 180 lists of outstanding issues). In practice, the total elapsed time from submission to a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is often 12 to 15 months. The European Commission then grants the formal marketing authorisation within approximately two months of a positive CHMP opinion, adding to the overall timeline.
One practical difference is that the FDA issues a single approval decision, whereas the EMA process concludes with a CHMP opinion that the European Commission must formally adopt. This two-step structure means that even after a positive scientific opinion, there is an additional administrative phase before a product can be marketed across EU Member States.
What is the difference between FDA approval and EMA marketing authorisation?
FDA approval is a direct regulatory decision issued by the agency itself, granting permission to market a drug or biologic in the United States. EMA marketing authorisation is a recommendation issued by the CHMP that the European Commission converts into a legally binding decision valid across all EU Member States plus Iceland, Liechtenstein, and Norway.
The scope of each decision also differs. An FDA approval is specific to the US market. An EMA centralised marketing authorisation, once granted by the European Commission, provides a single authorisation covering the entire EU, which represents a significant advantage for companies targeting multiple European markets simultaneously. However, pricing, reimbursement, and national-level access decisions remain the responsibility of individual Member States, so a marketing authorisation does not automatically translate into commercial availability everywhere in Europe. If you would like to understand how our team approaches these strategic considerations, visit our company page for more background on our expertise and experience.
Which regulatory pathway should a company choose first — FDA or EMA?
There is no universal answer, but the decision typically comes down to the company’s primary market, the product’s development stage, and available resources. Companies headquartered in or primarily targeting the US market often pursue FDA approval first. Those with strong European commercial infrastructure or products addressing conditions with higher European prevalence may prioritise the EMA pathway.
Several strategic considerations are worth weighing:
- Market size and commercial priority: The US remains the single largest pharmaceutical market, making FDA approval attractive for revenue generation
- Scientific advice: Both the FDA (through Pre-IND and Type B meetings) and the EMA (through Scientific Advice procedures) offer early engagement opportunities that can shape development programmes – using both in parallel is possible and often valuable
- Regulatory intelligence: A rejection or a request for additional data from one agency can inform and strengthen the submission to the other
- Parallel submissions: For well-resourced companies, submitting to both agencies simultaneously reduces time to market in both regions, though it requires careful coordination of dossier versions
For smaller companies or those with limited regulatory bandwidth, a sequential strategy with the FDA first is common, using the FDA review period to finalise and adapt the EMA dossier. Our regulatory services are designed to support companies at every stage of this process, whether they are pursuing a single-agency strategy or managing parallel submissions across multiple jurisdictions.
How do post-approval requirements differ between the FDA and EMA?
Post-approval obligations differ in both scope and mechanism. The FDA may impose post-marketing commitments or requirements as conditions of approval, including post-marketing studies and, where applicable, REMS programmes with specific elements to assure safe use. The FDA’s MedWatch system handles adverse event reporting, and companies must submit Periodic Adverse Drug Experience Reports (PADERs) or, for biologics, Periodic Safety Reports.
The EMA requires ongoing submission of Periodic Safety Update Reports (PSURs) according to a schedule set in the European Union Reference Date (EURD) list. EU pharmacovigilance legislation, introduced through Directive 2010/84/EU and Regulation (EU) No 1235/2010, places substantial obligations on Marketing Authorisation Holders, including maintaining a Pharmacovigilance System Master File (PSMF) and implementing the approved Risk Management Plan. Variations to the marketing authorisation, whether minor or major, must also be submitted and approved through the EMA’s variation procedure before changes can be implemented, which adds a layer of regulatory management that differs from the FDA’s Changes Being Effected (CBE) and Prior Approval Supplement (PAS) system.
How Starodub supports your FDA and EMA regulatory submissions
Navigating the differences between FDA and EMA regulatory submissions requires both strategic thinking and deep technical expertise. At Starodub, we support biopharmaceutical and medical device companies at every stage of the submission process, whether they are targeting the US, the EU, or both markets simultaneously.
Here is what we bring to your regulatory programme:
- Dossier preparation and gap analysis: We review your existing documentation against both FDA and EMA requirements and identify what needs to be developed, adapted, or strengthened before submission
- Regulatory strategy development: We help you determine the right pathway, designation opportunities, and sequencing to optimise your route to approval in each jurisdiction
- Scientific advice support: We prepare briefing documents and coordinate interactions with both the FDA and EMA to align your development programme with agency expectations early
- Post-approval lifecycle management: We manage variations, renewals, PSURs, and other post-marketing obligations so your authorisation remains compliant and up to date
- CMC and quality documentation: With a strong foundation in regulatory CMC, we ensure your Module 3 documentation meets the specific expectations of each agency
Whether you are preparing your first regulatory submission or managing a complex global dossier, we are ready to help. Contact Starodub today to discuss your regulatory strategy and find out how we can support your path to market.
Related Articles
- How do you manage regulatory compliance across multiple international markets?
- How to Build and Maintain a Quality Management System for Medical Devices
- ATMP Regulation in Europe: What Developers of Cell and Gene Therapies Need to Know
- What regulatory affairs services do medical device companies need?
- What are the costs of medical device regulatory compliance?
This content was generated with the help of AI and it may contain mistakes
